Zynex, Inc. (NASDAQ: ZYXI) reported Q4 EPS of $0.09, $0.01 better than the analyst estimate of $0.08. Revenue for the quarter came in at $14.2 million versus the consensus estimate of $13.77 million.

2019 Fourth Quarter

• Revenue increased 52% year over year to $14.2 million
• Orders increased 129%
• Net income of $2.9 million; Diluted EPS $0.09
• Adjusted EBITDA increased 30% to $4.1 million
• Fourteenth consecutive quarter of positive net income

Thomas Sandgaard, CEO said: "In the fourth quarter, we posted revenue of $14.2 million, which is the highest quarterly revenue in the history of the Company and net income of $2.9 million. Orders grew 129% compared to the fourth quarter of 2018 up from 95% year-over-year growth in the third quarter.

"In the fourth quarter, we continued to focus on the execution of our growth strategy and the related growth of our sales force. We expect the addition of new sales reps to have an impact on order and revenue growth this year and going forward. In addition, we continue to invest in our infrastructure to support the increase in order volume.

"We continue to advocate for pain patients, and for physicians to prescribe our NexWave technology as the first line of defense in treating chronic and acute pain without side effects. We are dedicated to promoting our technology in an effort to remove patient addiction and other side effects from prescription opioids."

GUIDANCE:

Zynex, Inc. sees Q1 2020 revenue of $14-14.5 million, versus the consensus of $13.14 million.

Zynex, Inc. sees FY2020 revenue of $75-80 million, versus the consensus of $63.5 million.

• The estimate range for the first quarter revenue is between $14.0 and $14.5 million with Adjusted EBITDA between $2.3 and $2.8 million as we continue to invest in growing our sales force. The revenue estimate is approximately 52% to 58% above 2019 first quarter revenue of $9.2 million. First quarter revenue is historically affected by health insurance deductibles not being met in the beginning of the year.
• Full year 2020 revenue is estimated between $75.0 and $80.0 million with Adjusted EBITDA between $15.0 and $18.0 million. The full year revenue estimate is approximately 65% to 76% above 2019 revenue of $45.5 million.

For earnings history and earnings-related data on Zynex, Inc. (ZYXI) click here.